Juha Punnonen

USPTO Granted Patents = 30 (Patent Applications = 3)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 2 (Patent Applications = 6)

Average Co-Inventor Count = 4.2

ph-index = 10

Forward Citations = 304(Granted Patents)

Location History:

Palo Alto, CA (US) (2003 - 2006)
Belmont, CA (US) (2006 - 2023)

Company Filing History:

Perseid Therapeutics LLC

Merck Sharp + Dohme Corp.

Years Active: 2003-2025

Loading Chart...

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12358986 - Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents (2025-07-15),

2. 11649290 - CTLA4 binders (2023-05-16),

3. 10544222 - PD1/CTLA4 binders (2020-01-28),

4. 10501542 - CTLA4 binders (2019-12-10),

5. 9657024 - Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival (2017-05-23),

6. 9186397 - Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein (2015-11-17),

7. 9163027 - Substituted triazolo-pyrimidine compounds for modulating cell proliferation differentiation and survival (2015-10-20),

8. 8715694 - Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein (2014-05-06),

9. 8496935 - Immunosuppressive polypeptides and nucleic acids (2013-07-30),

10. 8491899 - Immunosuppressive polypeptides and nucleic acids (2013-07-23),

11. 8445230 - Immunosuppressive polypeptides and nucleic acids (2013-05-21),

12. 8318176 - Immunosuppressive polypeptides and nucleic acids (2012-11-27),

13. 8283447 - Immunosuppressive polypeptides and nucleic acids (2012-10-09),

14. 8268587 - Immunosuppressive polypeptides and nucleic acids (2012-09-18),

15. 8168772 - Nucleic acids encoding novel chimeric C15/prM/E dengue virus immunogens prepared by DNA shuffling (2012-05-01),

Title: Innovation Extraordinaire: The Journey of Juha Punnonen

Introduction:

Juha Punnonen, a visionary inventor, hails from Belmont, CA, with an impressive record of 29 patents under his belt. His groundbreaking work has revolutionized the fields of immunotherapy and infectious disease treatment, earning him a well-deserved place among the top innovators of our time.

Latest Patents:

Juha Punnonen's recent patents include CTLA4 binders and PD1/CTLA4 binders. These molecules, such as ISVDs and Nanobodies, have been meticulously engineered to enhance immune response, combat cancer, and treat infectious diseases effectively. By reducing the incidence of binding by pre-existing antibodies, Punnonen's inventions offer new pathways for advanced medical treatments.

Career Highlights:

With a rich background in research and development, Juha Punnonen has made significant contributions to companies like Maxygen, Inc. and Perseid Therapeutics LLC. His expertise and dedication have led to the successful realization of cutting-edge technologies that continue to shape the healthcare industry.

Collaborations:

Throughout his career, Juha Punnonen has collaborated with esteemed professionals, including Steven Henry Bass and Erik E Karrer. Together, they have synergized their talents and knowledge to push the boundaries of innovation, leading to the creation of transformative solutions in biotechnology.

Conclusion:

In conclusion, Juha Punnonen stands as a beacon of creativity and ingenuity in the realm of inventions. His relentless pursuit of excellence and passion for pioneering advancements have left an indelible mark on the landscape of healthcare innovation. The world eagerly anticipates his next groundbreaking breakthrough as he continues to redefine the possibilities of medical science.

This text is generated by artificial intelligence and may not be accurate.